Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) fell 4.1% on Thursday . The stock traded as low as $12.35 and last traded at $12.39. 237,476 shares were traded during mid-day trading, a decline of 38% from the average session volume of 381,444 shares. The stock had previously closed at $12.92.
Analyst Ratings Changes
A number of equities analysts have issued reports on BCAX shares. Stifel Nicolaus started coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They set a "buy" rating and a $47.00 target price for the company. RODMAN&RENSHAW upgraded Bicara Therapeutics to a "strong-buy" rating in a report on Tuesday, November 5th. TD Cowen initiated coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They set a "buy" rating for the company. HC Wainwright started coverage on Bicara Therapeutics in a report on Friday, December 6th. They issued a "buy" rating and a $42.00 target price on the stock. Finally, Morgan Stanley began coverage on Bicara Therapeutics in a research report on Tuesday, October 8th. They set an "overweight" rating and a $35.00 price target for the company. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Bicara Therapeutics presently has an average rating of "Buy" and an average target price of $43.00.
View Our Latest Report on BCAX
Bicara Therapeutics Price Performance
The firm has a 50-day moving average price of $18.11.
Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($1.14). On average, analysts predict that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Bicara Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of BCAX. SG Americas Securities LLC bought a new position in Bicara Therapeutics during the fourth quarter worth $147,000. Cinctive Capital Management LP bought a new stake in Bicara Therapeutics in the third quarter valued at $229,000. Barclays PLC acquired a new position in shares of Bicara Therapeutics during the third quarter valued at $255,000. Jane Street Group LLC bought a new position in Bicara Therapeutics in the 3rd quarter worth about $309,000. Finally, Teachers Retirement System of The State of Kentucky bought a new position in Bicara Therapeutics in the 3rd quarter worth approximately $358,000.
Bicara Therapeutics Company Profile
(
Get Free Report)
Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
See Also
Before you consider Bicara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicara Therapeutics wasn't on the list.
While Bicara Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
